CAG25

posted on October 1, 2009 - 10:11am
The following story includes items about: Becker muscular dystrophy, centronuclear myopathy, type 1A Charcot-Marie-Tooth disease, congenital muscular dystrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, Miyoshi myopathy (distal muscular dystrophy), type 1 myotonic muscular dystrophy, myotubular myopathy, nemaline myopathy, and spinal muscular atrophy
posted on October 1, 2009 - 10:11am
QUEST Vol. 16, No. 4
The following story includes items about: Becker muscular dystrophy, centronuclear myopathy, type 1A Charcot-Marie-Tooth disease, congenital muscular dystrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, Miyoshi myopathy (distal muscular dystrophy), type 1 myotonic muscular dystrophy, myotubular myopathy, nemaline myopathy, and spinal muscular atrophy

Compound frees a crucial protein from a cellular trap in mice with MMD1; treatment prospects 'bright'

posted on July 17, 2009 - 4:03pm
Researchers at the University of Rochester (N.Y.) Wellstone Muscular Dystrophy Cooperative Research Center have identified a compound that has the potential to be developed into a treatment for type 1 myotonic dystrophy (MMD1, or DM1). The compound, dubbed CAG25, is an "antisense oligonucleotide," a type of construct that's been used to block disease-causing genetic instructions in laboratory...

Treatment prospects “bright”

posted on July 1, 2009 - 4:09pm
Researchers at the University of Rochester (N.Y.) Wellstone Muscular Dystrophy Cooperative Research Center have identified a compound that has the potential to be developed into a treatment for type 1 myotonic dystrophy (MMD1, or DM1). The compound, dubbed CAG25, is an "antisense oligonucleotide," a type of construct that's been used to block disease-causing genetic instructions in laboratory...